(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.